Biodesix, Inc. (NASDAQ:BDSX) Given Average Recommendation of “Moderate Buy” by Brokerages

Posted by Geri Gentry on Jun 24th, 2026

Shares of Biodesix, Inc. (NASDAQ:BDSX – Get Free Report) have earned an average rating of “Moderate Buy” from the five brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $26.50.

Several brokerages recently issued reports on BDSX. HC Wainwright began coverage on Biodesix in a research report on Monday, June 15th. They issued a “buy” rating and a $26.00 price target on the stock. Roth Mkm began coverage on Biodesix in a research report on Wednesday. They issued a “buy” rating on the stock. Canaccord Genuity Group boosted their price target on Biodesix from $22.00 to $27.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Weiss Ratings upgraded Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 12th. Finally, William Blair upgraded Biodesix from a “market perform” rating to an “outperform” rating in a research report on Friday, February 27th.

Check Out Our Latest Report on Biodesix

Institutional Investors Weigh In On Biodesix

Institutional investors have recently modified their holdings of the company. Cetera Investment Advisers purchased a new position in shares of Biodesix during the 4th quarter worth $68,000. Walleye Capital LLC purchased a new position in shares of Biodesix during the 1st quarter worth $157,000. Thompson Davis & CO. Inc. purchased a new position in shares of Biodesix during the 1st quarter worth $170,000. Renaissance Technologies LLC purchased a new position in shares of Biodesix during the 1st quarter worth $173,000. Finally, Millennium Management LLC purchased a new position in shares of Biodesix during the 3rd quarter worth $113,000. Hedge funds and other institutional investors own 20.96% of the company’s stock.

Biodesix Trading Down 2.6%

Shares of NASDAQ BDSX traded down $0.49 during trading on Wednesday, reaching $18.67. The stock had a trading volume of 108,608 shares, compared to its average volume of 784,910. Biodesix has a fifty-two week low of $5.01 and a fifty-two week high of $20.21. The company has a debt-to-equity ratio of 5.09, a quick ratio of 2.82 and a current ratio of 2.82. The business’s 50-day moving average price is $14.39 and its 200-day moving average price is $12.43. The company has a market cap of $193.35 million, a P/E ratio of -4.60 and a beta of 0.59.

Biodesix (NASDAQ:BDSX – Get Free Report) last released its earnings results on Monday, May 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.32. The firm had revenue of $25.56 million during the quarter, compared to analyst estimates of $23.12 million. Biodesix had a negative return on equity of 2,101.40% and a negative net margin of 33.26%. On average, equities research analysts predict that Biodesix will post -2.93 EPS for the current fiscal year.

About Biodesix

(Get Free Report)

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.